WHO Information Leaflet COVID-19: Considerations on tuberculosis (TB) care
Drugs, Diagnostics, Vaccines, Preventive Technologies, Research toward a cure, and immune-based and gene therapies in development
Following review of the latest evidence, WHO recommends that TB-LAMP can be used as a replacement for microscopy for the diagnosis of pulmonary TB in adults with signs and symptoms of ...ttribute-to-highlight medbox">TB. It can also be considered as a follow-on test to microscopy in adults with signs and symptoms of pulmonary TB, especially when further testing of sputum smear-negative specimens is necessary.
more
In the framework of the United Nations Sustainable Development Goals Issue-based Coalition on Health and Well-being for All at All Ages in Europe and Central Asia
In 2020, the COVID-19 pandemic impacted the world beyond imagination. To date, it has infected more than 135 million people, killed over 2.9 million people, and is projected to plunge up to 115 million people into extreme poverty.1 As countries have gone into lockdown, gender-based violence has incr...eased, unemployment has soared, and access to health care for the poorest and most vulnerable has been cut. COVID-19 has made people less likely to seek health care because they are afraid of getting infected with the virus. Fear and uncertainty surrounding COVID-19 have also increased stigma and discrimination. As frontline workers without enough access to personal protective equipment (PPE) risk their lives to treat patients, the virus pushes already fragile health systems to the brink.
more
The goal of this Global Action Plan is to articulate synergistic actions that will be required to prevent HIVDR from undermining efforts to achieve global targets on health and HIV, and to provide the most effective treatment to all people living with HIV including adults, key populations, pregnant ...and breastfeeding women, children and adolescents. The Global Action Plan has five strategic objectives: 1) prevention and response; 2) monitoring and surveillance; 3) research and innovation; 4) laboratory capacity; and 5) governance and enabling mechanisms.
more
BMJ,Dodd PJ, et al. Thorax 2017;72:559–575. doi:10.1136/thoraxjnl-2016-209421
PLOS ONE | DOI:10.1371/journal.pone.0144057 December 14, 2015
20 April 2022. The response to the COVID-19 pandemic continues to adversely affect essential TB services in many countries. A first report of case studies was published in 2021 comprising 23 examples of innovative interventions implemented by countr...ies to effectively respond to disruptions of TB services caused or exacerbated by the COVID-19 pandemic. This second, consolidated report incorporates new case studies, as well as updates to previously reported case studies
more
La nueva hoja de ruta para poner fin a la TB en la población infantil y adolescente tiene un amplio público destinatario y alentamos a los países a que la adapten en función de su contexto nacional. Se prevé que utilicen la hoja de ruta los enc...argados de formular políticas a nivel nacional, regional y mundial; los programas nacionales relacionados con la TB, la salud maternoinfantil, la infección por el VIH y otros programas de atención primaria de salud que formulan estrategias y planes sobre los servicios de salud. También será útil para los profesionales de salud en los servicios públicos y privados, las organizaciones de la sociedad civil y los organismos técnicos que participa
more
Time for recognition of lay counsellors
Accessed November 2017
GDF is the largest global provider of quality-assured tuberculosis (TB)
medicines, diagnostics, and laboratory supplies to the public sector.
Since 2001, GDF has facilitated access to high-quality TB...an> care in over 130
countries, providing treatments to over 30 million people with TB and procuring
and delivering more than $200 million worth of diagnostic equipment
more